Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Inogen stock | 29.14

Own Inogen stock in just a few minutes.

Posted

Fact checked

Inogen, Inc is a medical devices business based in the US. Inogen shares (INGN) are listed on the NASDAQ and all prices are listed in US Dollars. Inogen employs 1,020 staff and has a trailing 12-month revenue of around USD$330.9 million.

How to buy shares in Inogen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Inogen. Find the stock by name or ticker symbol: INGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inogen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$29.14, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Inogen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Inogen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Inogen's share price?

Since the stock market crash in March caused by coronavirus, Inogen's share price has had significant negative movement.

Its last market close was USD$29.14, which is 33.97% down on its pre-crash value of USD$44.13 and 7.10% down on the lowest point reached during the March crash when the shares fell as low as USD$31.21.

If you had bought USD$1,000 worth of Inogen shares at the start of February 2020, those shares would have been worth USD$1,074.08 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$647.20.

Inogen share price

Use our graph to track the performance of INGN stocks over time.

Inogen shares at a glance

Information last updated 2020-10-21.
Latest market closeUSD$29.14
52-week rangeUSD$26.57 - USD$76.89
50-day moving average USD$29.0134
200-day moving average USD$35.9393
Wall St. target priceUSD$34.33
PE ratio 106.3793
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.285

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks
N/A
0%
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Inogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inogen price performance over time

Historical closes compared with the close of $29.14 from 2020-10-19

1 week (2020-10-15) -5.54%
1 month (2020-09-22) 0.69%
3 months (2020-07-22) -16.67%
6 months (2020-04-22) -39.04%
1 year (2019-10-22) -42.64%
2 years (2018-10-22) -85.64%
3 years (2017-10-20) -69.85%
5 years (2015-10-22) -26.75%

Is Inogen under- or over-valued?

Valuing Inogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Inogen's P/E ratio

Inogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 106x. In other words, Inogen shares trade at around 106x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Inogen's PEG ratio

Inogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.48. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Inogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Inogen's EBITDA

Inogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$15.7 million.

The EBITDA is a measure of a Inogen's overall financial performance and is widely used to measure a its profitability.

Inogen financials

Revenue TTM USD$330.9 million
Gross profit TTM USD$171.9 million
Return on assets TTM -0.23%
Return on equity TTM 1.89%
Profit margin 1.96%
Book value $15.912
Market capitalisation USD$625.4 million

TTM: trailing 12 months

Shorting Inogen shares

There are currently 2.3 million Inogen shares held short by investors – that's known as Inogen's "short interest". This figure is 4.1% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Inogen shares can be evaluated.

Inogen's "short interest ratio" (SIR)

Inogen's "short interest ratio" (SIR) is the quantity of Inogen shares currently shorted divided by the average quantity of Inogen shares traded daily (recently around 219635.79766537). Inogen's SIR currently stands at 10.28. In other words for every 100,000 Inogen shares traded daily on the market, roughly 10280 shares are currently held short.

However Inogen's short interest can also be evaluated against the total number of Inogen shares, or, against the total number of tradable Inogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inogen's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Inogen shares in existence, roughly 100 shares are currently held short) or 0.2374% of the tradable shares (for every 100,000 tradable Inogen shares, roughly 237 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Inogen.

Find out more about how you can short Inogen stock.

Inogen share dividends

We're not expecting Inogen to pay a dividend over the next 12 months.

Inogen share price volatility

Over the last 12 months, Inogen's shares have ranged in value from as little as $26.57 up to $76.89. A popular way to gauge a stock's volatility is its "beta".

INGN.US volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inogen's is 0.7783. This would suggest that Inogen's shares are less volatile than average (for this exchange).

Inogen overview

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Frequently asked questions

More guides on finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site